Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Travoprost Intracameral Implant exchanged at Month 12
Travoprost Intracameral exchanged at Month 12 · 1 trial · 2 indications
concentration of travoprost free acid (ng/mL) in the aqueous humor 12 months post-administration as assessed by liquid chromatography tandem mass spectrometry (LC-MS/MS)
concentration of travoprost free acid (ng/mL) in the aqueous humor 3 months post-administration as assessed by LC-MS/MS
concentration of travoprost free acid (ng/mL) in the aqueous humor 6 months post-administration as assessed by LC-MS/MS
concentration of travoprost free acid (ng/mL) in the aqueous humor 24 months post-administration as assessed by LC-MS/MS
concentration of travoprost free acid (ng/mL) in the aqueous humor 21 months post-administration as assessed by LC-MS/MS
concentration of travoprost free acid (ng/mL) in the aqueous humor 18 months post-administration as assessed by LC-MS/MS
concentration of travoprost free acid (ng/mL) in the aqueous humor 15 months post-administration as assessed by LC-MS/MS
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (12-month exchange) | EXPERIMENTAL | Travoprost Intracameral Implant Exchanged at Month 12 |
| Cohort 2 (3-month exchange) | EXPERIMENTAL | Travoprost Intracameral Implant Exchanged at Month 3 |
| Cohort 3 (6-month exchange) | EXPERIMENTAL | Travoprost Intracameral Implant Exchanged at Month 6 |
| Cohort 4 (24-month exchange) | EXPERIMENTAL | Travoprost Intracameral Implant Exchanged at Month 24 |
| Cohort 5 (21-month exchange) | EXPERIMENTAL | Travoprost Intracameral Implant Exchanged at Month 21 |
| Cohort 6 (18-month exchange) | EXPERIMENTAL | Travoprost Intracameral Implant Exchanged at Month 18 |
| Cohort 7 (15-month exchange) | EXPERIMENTAL | Travoprost Intracameral Implant Exchanged at Month 15 |
| Name | Type | Description |
|---|---|---|
| Travoprost Intracameral Implant exchanged at Month 12 | DRUG | intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12 |
| Travoprost Intracameral Implant exchanged at Month 3 | DRUG | intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3 |
| Travoprost Intracameral Implant exchanged at Month 6 | DRUG | intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6 |
| Travoprost Intracameral Implant exchanged at Month 24 | DRUG | intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24 |
| Travoprost intracameral implant exchanged at Month 21 | DRUG | intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21 |
| Travoprost intracameral implant exchanged at Month 18 | DRUG | intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18 |
| Travoprost intracameral implant exchanged at Month 15 | DRUG | intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15 |
Inclusion Criteria: * Diagnosis of either open angle glaucoma (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or ocular hypertenson * Zero to three topical intraocular pressure lowering medications at the time of Visit 1 (Screening) exam. * Best spectacle corrected visual acuity of 16 let...
Travoprost Intracameral is an investigational small-molecule therapy being studied for open-angle glaucoma and ocular hypertension. It is designed to lower intraocular pressure in patients with these conditions. The implant is placed inside the eye and is being developed by Glaukos Corporation as a sustained-release treatment option.
Travoprost Intracameral targets the prostaglandin F receptor, also known as PTGFR, where it acts as an agonist. By activating this receptor, the drug increases aqueous humor outflow from the eye, which helps reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Glaukos Corporation is developing Travoprost Intracameral. The company trades on the New York Stock Exchange under the ticker symbol GKOS. Glaukos is focused on ophthalmic therapies, and this implant is part of its pipeline for glaucoma and ocular hypertension.
Travoprost Intracameral is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. The Phase 2 trial has been completed, and the program remains in clinical testing for open-angle glaucoma and ocular hypertension.
Travoprost Intracameral has been studied in one completed Phase 2 trial, NCT06582732, titled Performance of the Travoprost Intraocular Implant. The trial enrolled 210 participants with open-angle glaucoma or ocular hypertension and was conducted in Armenia. It used a controlled design and included adults aged 18 years and older.
Yes, Travoprost Intracameral is also known as Travoprost Intracameral Implant exchanged at Month 12. Both names refer to the same investigational product being developed by Glaukos Corporation for open-angle glaucoma and ocular hypertension. The alternative name reflects the implant exchange procedure performed at the 12-month time point.